DekaBank Deutsche Girozentrale’s Crinetics Pharmaceuticals CRNX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,300	Closed	-$546K	–	1169
2025 Q4	$546K	Hold	11,300	–	–	﹤0.01%	979
2025 Q3	$486K	Hold	11,300	–	–	﹤0.01%	993
2025 Q2	$340K	Hold	11,300	–	–	﹤0.01%	1044
2025 Q1	$388K	Hold	11,300	–	–	﹤0.01%	1008
2024 Q4	$577K	Hold	11,300	–	–	﹤0.01%	973
2024 Q3	$570K	Hold	11,300	–	–	﹤0.01%	988
2024 Q2	$492K	Hold	11,300	–	–	﹤0.01%	1009
2024 Q1	$498K	Hold	11,300	–	–	﹤0.01%	1002
2023 Q4	$402K	Hold	11,300	–	–	﹤0.01%	1085
2023 Q3	$333K	Hold	11,300	–	–	﹤0.01%	1102
2023 Q2	$200K	Hold	11,300	–	–	﹤0.01%	1163
2023 Q1	$177K	Hold	11,300	–	–	﹤0.01%	1198
2022 Q4	$206K	Hold	11,300	–	–	﹤0.01%	1214
2022 Q3	$214K	Hold	11,300	–	–	﹤0.01%	1216
2022 Q2	$198K	Hold	11,300	–	–	﹤0.01%	1189
2022 Q1	$215K	Buy	11,300 +1,000	+10%	+$20.2K	﹤0.01%	1196
2021 Q4	$276K	Buy	10,300 +300	+3%	+$7.4K	﹤0.01%	1211
2021 Q3	$205K	Hold	10,000	–	–	﹤0.01%	1204
2021 Q2	$187K	Hold	10,000	–	–	﹤0.01%	1230
2021 Q1	$154K	Hold	10,000	–	–	﹤0.01%	1235
2020 Q4	$129K	Buy	+10,000	New	+$139K	﹤0.01%	1248
2019 Q1	–	Sell	-11,000	Closed	-$330K	–	1209
2018 Q4	$330K	Buy	+11,000	New	+$310K	﹤0.01%	899

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CRNX Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 11,300 shares — an estimated $546K sold.

DekaBank Deutsche Girozentrale first reported a position in CRNX in Q4 2018 and held it in 22 quarters. The position peaked at $577K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 11,300 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $546K.
DekaBank Deutsche Girozentrale first reported a position in Crinetics Pharmaceuticals in Q4 2018 and held it in 22 quarters.
DekaBank Deutsche Girozentrale's Crinetics Pharmaceuticals position peaked at $577K in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.